# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-09-2024 | 03-31-2024 | 10-Q | |
2 | 03-15-2024 | 12-31-2023 | 10-K | |
3 | 11-14-2023 | 09-30-2023 | 10-Q | |
4 | 08-14-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://patentcenter.uspto.gov/applications/16890552/ifw/docs
ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approxim...
ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndromeTopical application of ATR-12 to ex vivo...